Podcasts about Interferon

Die Auswertung vieler Studien weltweit hat gezeigt, das die Basistherapie das beste Mittel gegen das Voranschreiten der MS ist. Du kannst den Beitrag auf meinem Blog Nachlesen: https://ms-perspektive.de/podcast-005-die-basistherapie Der folgende Beitrag ist ein Update zu Folge 5, in der es um die Basistherapie geht, ergänzt um meine Erkenntnisse aus den vergangenen fünf Jahren und meinem Multiple Sklerose Management Studium. Die Bedeutung der Immuntherapie ist heute klarer denn je: Sie kann das Fortschreiten der MS verlangsamen und mögliche Einschränkungen hinauszögern. In diesem Beitrag teile ich aktuelle wissenschaftliche Erkenntnisse, neue Therapieoptionen und meine persönlichen Erfahrungen. Zudem erfährst du, warum eine frühzeitige Basistherapie so wichtig ist und welche Entwicklungen es in der MS-Forschung gibt. Inhaltsverzeichnis Update zur Basistherapie Fortschritte in der Forschung Bedeutung der Präzisionsmedizin Einführung in die Basistherapie Rückblick auf persönliche Erfahrungen Empfehlungen zur sofortigen Therapie Der Weg mit meiner Basistherapie Schwangerschaft und Therapieanpassungen Anpassung der Therapie Buchveröffentlichung und weitere Informationen Medikamente und deren Wirksamkeit Überwinde deine Ängste vor der Basistherapie! Wichtige Erkenntnis zur MS und der neurologischen Reserve Zukunftsaussichten: Hoffnung auf Remyelinisierung Plädoyer für die Basistherapie Zusammenfassung – Die wichtigsten Punkte auf einen Blick: Mein persönliches Fazit: Weiterführende Infos zur Immuntherapie Mein persönliches Fazit: Das war heute mein dringendes Plädoyer für die Basistherapie. Ich wünsche dir, mir und allen anderen da draußen viel Gesundheit, viel Kraft und eine möglichst lange Zeit ohne Einschränkungen.

Matters Microbial #81: Viruses, Innate Immunity, and Undergraduates March 5, 2025 Today, Dr. Brianne Barker, Associate Professor of the Biology Department at Drew University, joins the #QualityQuorum to discuss how her undergraduate research group studies how innate immune mechanisms of cells recognize viral invasion. Host: Mark O. Martin Guest: Brianne Barker Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode A video describing the immune system, both innate and adaptive. More of a focus on mechanisms of innate immunity, the focus for today. A description of basic immune cells. An introductory video describing the viral reproductive cycle in general. A description of PRRs (pattern recognition receptors) and MAMPs (microbially associated molecular patterns) An overview of interferons and disease. An introductory video overview of programmed cell death, called apoptosis. The role that retroviruses play in producing blue eggs in chickens.  Here is a very introductory summary.   The role that retroviruses play in placental mammals, including humans. How do cells recognize invading DNA during viral infection? A research paper by Dr. Barker's research group. Dr. Barker on This Week in Virology. Dr. Barker's faculty website. Dr. Barker's research group website. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com

My guest is Dr. Roger Seheult, M.D., a board-certified physician in internal medicine, pulmonary diseases, critical care, and sleep medicine at Loma Linda University. We discuss the powerful benefits of light therapy, including infrared light, red light, and sunlight, for improving mitochondrial function in all the body's organs. We also explore ways to reduce the risk of influenza, colds, and other illnesses that affect the lungs, sinuses, and gut. Topics include the flu shot, whether handwashing truly prevents illness transmission, and treatments for long COVID and mold toxicity. We review the efficacy of N-acetylcysteine (NAC), the power of hydrotherapy for combating infections, and strategies for improving sleep and overall health. Additionally, we discuss air quality. This episode provides actionable, science-based tools for preventing and treating infectious illnesses. Read the full show notes for this episode at hubermanlab.com. Sponsors AG1: https://drinkag1.com/huberman Joovv: https://joovv.com/huberman Eight Sleep: https://eightsleep.com/huberman LMNT: https://drinklmnt.com/huberman Function: https://functionhealth.com/huberman Our Place: https://fromourplace.com/huberman Timestamps 00:00:00 Dr. Roger Seheult 00:02:16 Avoiding Sickness, Immune System, Tool: Pillars of Health, NEWSTART 00:08:03 Sponsors: Joovv & Eight Sleep 00:10:46 Sunlight, Mitochondria, Tool: Infrared Light & Melatonin 00:19:09 Melatonin Antioxidant, Reactive Oxygen Species (ROS)/Free Radicals 00:26:38 Infrared Light, Green Spaces, Health & Mortality 00:31:35 Infrared Light, Mitochondrial Dysfunction, Disease 00:38:46 Sunlight & Cancer Risk?, Tools: UV Light, Clothing & Sunlight Exposure 00:41:01 Sponsors: AG1 & LMNT 00:43:32 Sunlight, Incidence of Influenza or COVID 00:48:41 Tools: Sunlight Exposure Duration, Winter Months 00:55:18 Infrared Lamps?, Winter Sunlight Exposure; Obesity & Metabolic Dysfunction 00:59:48 Cloudy Days; Sunlight, Primitive Therapy, Hospitals 01:11:33 Sponsor: Function 01:13:21 Artificial Lights, Hospitals & Light Therapy?, ICU Psychosis 01:22:16 Sleep & Darkness, Tools: Eye Mask, Bathroom Navigation; Meals & Light 01:28:27 Influenza, Flu Shots, Swiss Cheese Model; Flu Shot Risks? 01:38:13 Masks?, Flu; Handwashing 01:42:16 Sponsor: Our Place 01:43:57 Water, Sodium; Innate Immune System, Fever & Hydrotherapy 01:53:46 Fever, Heat Hydrotherapy, Interferon & Immune System 01:58:25 Cold Hydrotherapy, Vasoconstriction & White Blood Cells 02:09:56 N-Acetyl Cysteine (NAC), Glutathione, White Clots, Flu, Covid 02:19:28 Tool: NAC Dose & Regimen; Mucous, Flu Symptoms 02:25:25 Zinc Supplementation, Copper; Exogenous Interferon 02:28:40 Eucalyptus Oil, Inhalation 02:32:22 Air, Smoking, Vaping, Nicotine Gum 02:36:49 Fresh Air, Forest Bathing, Tool: Go Outdoors 02:40:09 Nature vs Inside Environments, Dark Days/Bright Nights Problem 02:52:38 Long COVID, Mitochondrial Dysfunction, Intermittent Fasting, Sunlight 03:00:43 Covid & Varied Severity, Smell Loss Recovery 03:05:04 Mold Toxicity, Lungs, Germ vs Terrain Theory, Immunocompromised 03:11:46 Trust, Spirituality, Community, Faith; Forgiveness 03:19:46 Hospital Admission, Tool: Asking Questions 03:25:42 Zero-Cost Support, YouTube, Spotify & Apple Follow & Reviews, Sponsors, YouTube Feedback, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures

In this episode of the Pediatric and Developmental Pathology Podcast, our hosts Dr. Mike Arnold (@MArnold_PedPath) and Dr. Jason Wang speak with Dr. Jeff Terry of British Columbia Children's and Women's Hospitals about his article in Pediatric and Developmental Pathology: Interferon Gamma Expressing Mucosal Cells in Pediatric Chronic Inflammatory Bowel Disease   Featured public domain music: Summer Pride by Loyalty Freak

CatalYm is preparing to initiate its broad phase 2b clinical development program for visugromab to tackle multiple solid tumor indications. Visugromab is a monoclonal antibody that neutralizes the tumor-derived growth differentiation factor-15 (GDF-15), a locally acting immunosuppressant fostering immunotherapy resistance. Neutralizing GDF-15 with visugromab reverses key cancer resistance mechanisms to reinstate an efficient anti-tumor response by reenabling immune cell activation, proliferation and Interferon-γ signature induction. Visugromab has demonstrated a good safety profile and potent and durable anti-tumor efficacy in combination with anti-PD-1 treatment in advanced cancer patients, as highlighted in its recent Nature publication and interim clinical data. This week we have a conversation with Eugen Leo, chief medical officer at CatalYm.01:30-03:38: About CatalYm03:38-06:59: Solid tumors and also why they are hard to treat06:59-09:04: Current treatments for solid tumors09:04-10:47: What is immunotherapy resistance?10:47-12:23: What is visugromab?12:23-13:32: CatalYm's clinical development program13:32-15:12: What represents success for patients using visugromab?15:12-17:50: Other treatment options being developed17:50-19:50: CatalYm's pipeline and the futureThis week's podcast was sponsored by TCR Solutions.Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

In this week's episode we'll learn more about an experimental regimen for classical Hodgkin lymphoma that combines brentuximab vedotin, nivolumab, and chemotherapy; a possible role for type 1 interferon signaling in developing autoantibodies to red blood cells in sickle cell disease; and how genomic alterations affecting class I human leukocyte antigen molecules may affect patients with cutaneous T-cell lymphoma. Featured Articles:Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphomaIFN-I promotes T-cell–independent immunity and RBC autoantibodies via modulation of B-1 cell subsets in murine SCDGenetic alteration of class I HLA in cutaneous T-cell lymphoma

On episode #71 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 12/19/24 – 1/1/25. Hosts: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Routine detection of viruses through metagenomics: where do we stand? (ASTMH) Rapid selection of HIV-2 capsid mutations in salvage therapy with Lenacapavir-containing regime (CID) Bacterial Ancient genomes reveal a deep history of treponemal disease in the Americas (Nature) The utility of Interferon-γ release assays in the diagnosis of tuberculosis in patients With cancer(Transplant Infectious Disease) A meta-analysis of Levofloxacin for contacts of multidrug-resistant tuberculosis (NEJM Evidence) Tularemia— United States, 2011–2022 (CDC: MMWR) Incorporating incubation period distributions to precisely estimate the association between rainfall and Legionella infection (JID) Fungal The Last of US Season 2 (YouTube) Candida albicans recovered from persistent candidemia exhibit enhanced virulence traits (JID) Mapping the geographic distribution of dimorphic mycoses using a U.S. commercial insurance database (OFID) Comparative efficacy and safety of treatment regimens for Pneumocystis jirovecii pneumonia in people living with HIV – A systematic review and network meta-analysis of randomized controlled trials (CMI: Clinical Microbiology and Infection) Outbreak of Blastomycosis Among Paper Mill Workers — Michigan, November 2022–May 2023 (CDC: MMWR) Parasitic Acanthamoeba Infection in a hematopoietic cell transplant recipient: challenges in diagnosis, management, and source identification (Transplant Infectious Disease) Congenital toxoplasmosis: Fewer clinical signs at 3 years of age over the last 15 years but stable risk of materno-fetal transmission (CID) Miscellaneous Detection of prions in wild pigs (Sus scrofa) from areas with reported chronic wasting disease cases, United States (CDC Emerging Infectious Diseases) Addition of macrolide antibiotics for hospital treatment of community-acquired pneumonia (JID) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

In this episode, we sit down with Dr. Victoria Werth, a leading expert in dermatology and autoimmune diseases, to explore the study Understanding the Role of Type I Interferons in Cutaneous Lupus and Dermatomyositis: Toward Better Therapeutics. Dr. Werth delves into the complex immune mechanisms that drive skin manifestations in cutaneous lupus and dermatomyositis, two challenging autoimmune conditions. She explains how Type I interferons contribute to inflammation and tissue damage, and how understanding these pathways could pave the way for more targeted and effective treatment

Erfahre mehr über B-Zell-Depletionen, wie Ocrevus, Kesimpta, Bonspri, Mabthera, Rituxan und Briumvi, für aktive RRMS & SPMS und frühe PPMS. Du kannst den vollständigen Beitrag auf meinem Blog nachlesen: https://ms-perspektive.de/274-b-zell-depletion B-Zell-Depletions-Therapien wie Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Rituximab (Mabthera, Rituxan) und Ublituximab (Briumvi) sind zu wichtigen Instrumenten bei der Behandlung von Multipler Sklerose (MS) geworden. Diese Behandlungen zielen speziell auf B-Zellen ab, eine Art von Immunzellen, die am Entzündungsprozess von MS beteiligt sind, und reduzieren diese. B-Zell-Therapien gelten als einige der spezifischsten und wirksamsten verlaufsmodifizierenden Therapien, die heute verfügbar sind, und bieten einen maßgeschneiderten Ansatz zur Verringerung der Krankheitsaktivität und des Fortschreitens der MS. In diesem Beitrag geht es darum, wie diese Therapien innerhalb der MS-Behandlungsoptionen eingeordnet werden und was ihr Zulassungsstatus und ihre Wirksamkeit für verschiedene Patientengruppen bedeuten. Bitte beachte, dass ich hier nur einen Überblick geben kann. Deine Neurologin und MS-Schwester sollten dich ausführlich über die richtige Therapie für dich beraten. Sie kennen deinen allgemeinen Gesundheitszustand und du solltest auch über deine Ziele, Wünsche, Ängste und Vorlieben sprechen, damit diese berücksichtigt werden können. Inhaltsverzeichnis Allgemeine Informationen Wie werden B-Zell-Depletionen - Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Rituximab (Mabthera, Rituxan), Ublituximab (Briumvi) in den Immuntherapien eingeordnet? Wofür sind B-Zell-Depletionen - Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Rituximab (Mabthera, Rituxan), Ublituximab (Briumvi) zugelassen? Wie sieht die Situation für spezielle Patientengruppen aus? Wer sollte Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Rituximab (Mabthera, Rituxan), Ublituximab (Briumvi) vermeiden? Wie wirken Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Rituximab (Mabthera, Rituxan) und Ublituximab (Briumvi)? Wie wird es eingenommen? Wie wirksam sind Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Rituximab (Mabthera, Rituxan), Ublituximab (Briumvi)? Risiken und Nebenwirkungen von Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Rituximab (Mabthera, Rituxan), Ublituximab (Briumvi) Impfungen Quellen Schlussbemerkung Quellen Für die Erstellung des Inhalts habe ich folgende Quellen verwendet: Vorlesung über pädiatrische Multiple Sklerose von Prof. Dr. Jutta Gärtner im Rahmen des Masterstudiengangs Multiple-Sklerose-Management Vorlesung über B-Zell-depletierende Therapien von Prof. Dr. Xavier Montalban im Rahmen des Masterstudiengangs Multiple-Sklerose-Management Qualitätshandbuch der KKNMS zu Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Ublituximab (Briumvi) MS-Selfie-Infokarten von Prof. Dr. Gavin Giovannoni Deutschsprachiges Multiple Sklerose und Kinderwunschregister (DMSKW) Deutsche DECIMS-Informationen zu Ocrelizumab --- Vielleicht möchtest du auch einen Blick auf die Beiträge zu den anderen Immuntherapien werfen: #256: Dimethylfumarat (Tecfidera) und Diroximelfumarat (Vumerity) #258: Glatirameracetat (Copaxone, Brabio) #261: Interferon-beta (Avonex, Betaferon, Extavia, Plegridy, Rebif) #264: Teriflunomid (Aubagio) #266: Natalizumab (Tysabri, Tyruko)  #268: S1P-Modulatoren – Fingolimod (Gilenya), Ozanimod (Zeposia), Ponesimod (Ponvory), Siponimod (Mayzent) #270: Alemtuzumab (Lemtrada, Campath) bei hochaktiver Multipler Sklerose #272: Cladribin (Mavenclad, Leustatin, Litak) bei hochaktiver MS Bis bald und mach das Beste aus Deinem Leben, Nele Mehr Informationen und positive Gedanken erhältst Du in meinem kostenlosen Newsletter. Hier findest Du eine Übersicht zu allen bisherigen Podcastfolgen.

Cladribin (Mavenclad, Leustatin, Litak) ist eine Induktionstherapie, die das Immunsystem unterdrückt und bei hochaktiver MS eingesetzt wird. Hier findest Du den Blogbeitrag zum Nachlesen: https://ms-perspektive.de/272-cladribin Cladribin (Mavenclad, Leustatin, Litak) ist eine Immuntherapie aus dem Bereich der Immunsuppressiva, die zur Behandlung von hochaktiver Multipler Sklerose (MS) eingesetzt wird. Es gehört zur Klasse der verlaufsmodifizierenden Therapien, die das Immunsystem durch Depletion gezielt beeinflussen, um das Fortschreiten der Krankheit zu verhindern. Erfahre mehr über das Prinzip der Induktionstherapien, wie Cladribin funktioniert, wie wirksam es ist und welche potenziellen Risiken damit verbunden sind. Du lernst die Rolle von Cladribin in der MS-Therapie kennen, seine verschiedenen Formen und was PatientInnen wissen sollten, wenn sie diese Behandlung in Betracht ziehen, insbesondere im Hinblick auf Schwangerschaft, Stillen und langfristige Gesundheitsüberwachung. Bitte bedenke, dass ich hier nur einen Überblick geben kann. Dein Neurologe und deine MS-Schwester sollten dich ausführlich über die richtige Therapie für dich beraten. Das liegt daran, dass sie deinen allgemeinen Gesundheitszustand kennen und du auch über deine Ziele, Wünsche, Ängste und Vorlieben sprechen solltest, damit diese berücksichtigt werden können. Inhaltsverzeichnis Allgemeine Informationen Wie wird Cladribin (Mavenclad, Leustatin, Litak) bei den Immuntherapien eingestuft? Wofür ist Cladribin (Mavenclad, Leustatin, Litak) zugelassen? Wie sieht die Situation für spezielle Patientengruppen aus? Wer sollte Cladribin (Mavenclad, Leustatin, Litak) meiden? Wie wirkt Cladribin (Mavenclad, Leustatin, Litak)? Wie wird es eingenommen? Wie wirksam ist Cladribin (Mavenclad, Leustatin, Litak)? Risiken und Nebenwirkungen von Cladribin (Mavenclad, Leustatin, Litak) Impfungen Quellen Schlussbemerkung --- Vielleicht möchtest du auch einen Blick auf die Beiträge zu den anderen Immuntherapien werfen: #256: Dimethylfumarat (Tecfidera) und Diroximelfumarat (Vumerity) #258: Glatirameracetat (Copaxone, Brabio) #261: Interferon-beta (Avonex, Betaferon, Extavia, Plegridy, Rebif) #264: Teriflunomid (Aubagio) #266: Natalizumab (Tysabri, Tyruko)  #268: S1P-Modulatoren – Fingolimod (Gilenya), Ozanimod (Zeposia), Ponesimod (Ponvory), Siponimod (Mayzent) #270: Alemtuzumab (Lemtrada, Campath) bei hochaktiver Multipler Sklerose Bis bald und mach das Beste aus Deinem Leben, Nele Mehr Informationen und positive Gedanken erhältst Du in meinem kostenlosen Newsletter. Hier findest Du eine Übersicht zu allen bisherigen Podcastfolgen.

Alemtuzumab (Lemtrada) ist eine Induktionstherapie für hochaktive MS, wirkt lange und kann schwere Nebenwirkungen haben. Du kannst den kompletten Beitrag auf meinem Blog nachlesen: https://ms-perspektive.de/270-alemtuzumab Diesmal liegt der Fokus auf Alemtuzumab (Lemtrada, Campath). Es ist eine der hochwirksamen Immuntherapien und ermöglicht bei einer Untergruppe von Patienten mit hochaktiver MS sogar einen Krankheitsstillstand von mehr als fünf Jahren. Aufgrund seiner lang anhaltenden Wirkung auf das Immunsystem und der teilweise schweren Nebenwirkungen wird es relativ sparsam eingesetzt. Es wird als verlaufsmodifizierende Therapie bei aktiver Multipler Sklerose eingesetzt, sowohl bei schubförmigen Formen als auch, nach FDA-Zulassung, bei aktiver SPMS. Alemtuzumab führt aufgrund seines Wirkmechanismus zu einer sofortigen Immunzelldepletion von CD52-positiven Immunzellen (hauptsächlich T-Zellen und B-Zellen). Es wird daher beispielsweise bei Patienten mit massiver Entzündungsaktivität eingesetzt, bei denen das Risiko einer raschen Zunahme der Behinderung besteht. Bitte bedenke, dass ich hier nur einen Überblick geben kann. Dein Neurologe und deine MS-Krankenschwester sollten dich ausführlich über die für dich geeignete Therapie beraten. Denn sie kennen deinen allgemeinen Gesundheitszustand und du solltest auch über deine Ziele, Wünsche, Ängste und Vorlieben sprechen, damit diese berücksichtigt werden können. Inhaltsverzeichnis Allgemeine Informationen Wie wird Alemtuzumab (Lemtrada, Campath) bei den Immuntherapien eingeordnet? Wofür ist Alemtuzumab (Lemtrada, Campath) zugelassen? Wie sieht die Situation für spezielle Patientengruppen aus? Wer sollte Alemtuzumab (Lemtrada, Campath) meiden? Wie wirkt Alemtuzumab (Lemtrada, Campath)? Wie wird es eingenommen? Wie wirksam ist Alemtuzumab (Lemtrada, Campath)? Risiken und Nebenwirkungen von Alemtuzumab (Lemtrada, Campath) Impfungen Quellen Schlussbemerkung Quellen Ich habe die folgenden Quellen verwendet, um den Inhalt zu erstellen: Qualitätshandbuch der deutschen KKNMS zu Alemtuzumab (Lemtrada) MS-Selfie-Infokarten von Prof. Dr. Gavin Giovannoni Deutschsprachiges Multiple Sklerose Kinderwunschregister (DMSKW) Deutsche DECIMS-Informationen zu Alemtuzumab Schlussbemerkung Bitte denke daran, dass es kein Medikament gibt, das allen hilft, sondern dass immer abgewogen werden muss, was für eine bestimmte Person am besten geeignet ist. Auch andere Krankheiten, persönliche Ziele und Vorlieben müssen berücksichtigt werden. Deine Neurologin oder dein Neurologe und die MS-Schwester sind die richtigen Ansprechpartner und können individuelle Empfehlungen aussprechen. Dieser Beitrag dient nur zu Informationszwecken und stellt keine Empfehlung dar. Was der einen Person hilft, muss der anderen nicht helfen. Ich hoffe, dass du gemeinsam mit deinem Neurologen und deiner MS-Schwester schnell die richtige Immuntherapie für dich findest. Und dass du mit MS ein erfülltes, glückliches und selbstbestimmtes Leben führen kannst, unterstützt durch einen gesunden Lebensstil und eine Portion Glück. --- Vielleicht möchtest du auch einen Blick auf die Beiträge zu den anderen Immuntherapien werfen: #256: Dimethylfumarat (Tecfidera) und Diroximelfumarat (Vumerity) #258: Glatirameracetat (Copaxone, Brabio) #261: Interferon-beta (Avonex, Betaferon, Extavia, Plegridy, Rebif) #264: Teriflunomid (Aubagio) #266: Natalizumab (Tysabri, Tyruko)  #268: S1P-Modulatoren – Fingolimod (Gilenya), Ozanimod (Zeposia), Ponesimod (Ponvory), Siponimod (Mayzent) Bis bald und mach das Beste aus Deinem Leben, Nele Mehr Informationen und positive Gedanken erhältst Du in meinem kostenlosen Newsletter. Hier findest Du eine Übersicht zu allen bisherigen Podcastfolgen.

Erfahre mehr über die S1P-Modulatoren (Gilenya, Zeposia, Ponvory, Mayzent) und deren Einsatz bei aktiver schubförmiger MS und SPMS. Hier findest Du den Beitrag zum Nachlesen und mit allen Bildern: https://ms-perspektive.de/268-s1p-modulatoren Heute geht es um die Gruppe der S1P-Modulatoren, zu denen Fingolimod (Gilenya), Ozanimod (Zeposia), Ponesimod (Ponvory) und Siponimod (Mayzent) gehören. Die ersten drei, d. h. Gilenya, Zeposia und Ponvory, werden als verlaufsmodifizierende Therapie bei aktiver Multipler Sklerose eingesetzt. Fingolimod (Gilenya) ist sogar für pädiatrische MS zugelassen. Mayzent ist für aktive SPMS zugelassen, wenn der Patient bereits eine von Schüben unabhängige Verschlechterung der MS erfährt, aber auch eine lokalisierte Entzündungsaktivität aufweist. S1P-Modulatoren sind sogenannte Sphingosin-1-Phosphat-Rezeptormodulatoren und verhindern den Austritt von Lymphozyten aus den Lymphknoten. Dadurch wird auch verhindert, dass sie in das zentrale Nervensystem (ZNS) gelangen. Die Untergruppen der S1P-Rezeptoren bestimmen das Nebenwirkungsprofil. Bitte denke daran, dass ich hier nur einen Überblick geben kann. Dein Neurologe und deine MS-Schwester sollten dich ausführlich über die für dich richtige Therapie beraten. Denn sie kennen deinen aktuellen Gesundheitszustand und du solltest auch über deine Ziele, Wünsche, Ängste und Vorlieben sprechen, damit diese berücksichtigt werden können. Inhaltsverzeichnis Allgemeine Informationen Wie werden S1P-Modulatoren - Fingolimod (Gilenya), Ozanimod (Zeposia), Ponesimod (Ponvory), und Siponimod (Mayzent) - bei den Immuntherapien eingestuft? Wofür sind Fingolimod (Gilenya), Ozanimod (Zeposia), Ponesimod (Ponvory) und Siponimod (Mayzent) zugelassen? Wie sieht die Situation für spezielle Patientengruppen aus? Wer sollte Fingolimod (Gilenya), Ozanimod (Zeposia), Ponesimod (Ponvory) und Siponimod (Mayzent) vermeiden? Wie wirken Fingolimod (Gilenya), Ozanimod (Zeposia), Ponesimod (Ponvory) und Siponimod (Mayzent)? Wie wird es eingenommen? Wie wirksam sind Fingolimod (Gilenya), Ozanimod (Zeposia), Ponesimod (Ponvory) und Siponimod (Mayzent)? Risiken und Nebenwirkungen von Fingolimod (Gilenya), Ozanimod (Zeposia), Ponesimod (Ponvory) und Siponimod (Mayzent) Impfungen Quellen Schlussbemerkung Quellen Für die Erstellung der Inhalte habe ich die folgenden Quellen verwendet: Vorlesung über S1P-Rezeptor-Modulator von Prof. Dr. Tobias Derfuss im Rahmen des Masterstudiengangs Multiple Sklerose Management Qualitätshandbuch der deutschen KKNMS zu Fingolimod (Gilenya),Ozanimod (Zeposia),Ponesimod (Ponvory)und Siponimod (Mayzent) MS-Selfie Infokarten von Prof. Dr. Gavin Giovannoni Deutschsprachiges Multiple Sklerose und Kinderwunschregister (DMSKW) Informationen aus dem deutschen Interview mit Prof. Dr. Barbara Kornek über pädiatrische MS Deutsche DECIMS-Informationen zu Fingolimod --- Vielleicht möchtest du auch einen Blick auf die Beiträge zu den anderen Immuntherapien werfen: #256: Dimethylfumarat (Tecfidera) und Diroximelfumarat (Vumerity) #258: Glatirameracetat (Copaxone, Brabio) #261: Interferon-beta (Avonex, Betaferon, Extavia, Plegridy, Rebif) #264: Teriflunomid (Aubagio) #266: Natalizumab (Tysabri, Tyruko) für aktive schubförmig remittierende MS Bis bald und mach das Beste aus Deinem Leben, Nele Mehr Informationen und positive Gedanken erhältst Du in meinem kostenlosen Newsletter. Hier findest Du eine Übersicht zu allen bisherigen Podcastfolgen.

Immune discusses two stories of immune cells eating other cells: microglia engulfing brain neurons to shape cortical development and behavior, and mast cells trapping neutrophils to increase their functional and metabolic fitness. Hosts: Vincent Racaniello, Cindy Leifer, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server Microglia shape cortical development and behavior (Cell) Neutrophil trapping by mast cells (Cell) Time stamps by Jolene. Thanks! Music by Steve Neal. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv

Natalizumab (Tysabri, Tyruko) wird für aktive schubförmig remittierende MS eingesetzt als Infusion oder Spritze und wirkt sehr schnell. Den kompletten Beitrag zum Nachlesen findest Du auf meinem Blog: https://ms-perspektive.de/266-natalizumab Heute geht es um Natalizumab, das unter den Handelsnamen Tysabri und Tyruko bekannt ist. Die Immuntherapie wird bei aktiven, schweren Verläufen von schubförmiger MS eingesetzt. Natalizumab ist ein migrationshemmendes Medikament, das die Einwanderung von T- und B-Zellen in das zentrale Nervensystem verhindert. Bitte denke daran, dass ich hier nur einen Überblick geben kann. Dein Neurologe und deine MS-Schwester sollten dich bei der Wahl der richtigen Therapie ausführlich beraten. Denn sie kennen deinen allgemeinen Gesundheitszustand und du solltest auch über deine Ziele, Wünsche, Ängste und Vorlieben sprechen, damit diese berücksichtigt werden können. Inhaltsverzeichnis Allgemeine Informationen Wie wird Natalizumab (Tysabri, Tyruko) bei den Immuntherapien eingestuft? Wofür ist Natalizumab (Tysabri, Tyruko) zugelassen? Wie sieht die Situation für spezielle Patientengruppen aus? Wer sollte Natalizumab meiden? Wie wirkt Natalizumab? Wie wird es eingenommen? Wie wirksam ist Natalizumab (Tysabri, Tyruko)? Risiken und Nebenwirkungen von Natalizumab (Tysabri, Tyruko) Impfungen Quellen Schlussbemerkung Quellen Für die Erstellung der Inhalte habe ich die folgenden Quellen verwendet: Vorlesung zu Natalizumab von Prof. Dr. Thomas Berger im Rahmen des Masterstudiengangs Multiple Sklerose Management Qualitätshandbuch der deutschen KKNMS zu Natalizumab (Tysabri, Tyruko) MS-Selfie Infokarten von Prof. Dr. Gavin Giovannoni Deutsches Multiple Sklerose- und Kinderwunsch-Register (DMSKW) Informationen aus dem deutschen Interview mit Prof. Dr. Barbara Kornek über pädiatrische MS Deutsche DECIMS-Informationen zu Natalizumab --- Vielleicht möchtest du auch einen Blick auf die Beiträge zu den anderen Immuntherapien werfen: #256: Dimethylfumarat (Tecfidera) und Diroximelfumarat (Vumerity) #258: Glatirameracetat (Copaxone, Brabio) #261: Interferon-beta (Avonex, Betaferon, Extavia, Plegridy, Rebif) #264: Teriflunomid (Aubagio) Bis bald und mach das Beste aus Deinem Leben, Nele Mehr Informationen und positive Gedanken erhältst Du in meinem kostenlosen Newsletter. Hier findest Du eine Übersicht zu allen bisherigen Podcastfolgen.

Immune reviews the local and systemic responses after human SARS-CoV-2 challenge infection, and how bat antibodies display elevated antigen binding strength and diversity at higher temperatures that are characteristic of flight. Hosts: Vincent Racaniello, Cindy Leifer, Stephanie Langel and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server Responses to human SARS-CoV-2 challenge (Nature) Temperature-sensitivity of bat antibodies (Nat Comm) Time stamps by Jolene. Thanks! Music by Steve Neal. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv

Interferon-beta wie Avonex, Betaferon, Extavia, Plegridy, Rebif und Generika können für milde und moderate Verläufe der MS eingesetzt werden. Den vollständigen Beitrag zum Nachlese findest Du auf meinem Blog: https://ms-perspektive.de/261-interferone Im heutigen Artikel stelle ich Interferon-beta vor, das mehrere Wirkstoffe enthält und unter den Namen Avonex, Betaferon, Extavia, Plegridy, Rebif oder anderen Handelsnamen bekannt ist. Sie alle sind zugelassene verlaufsmodifizierende Medikamente für die schubförmige MS. Wie Glatirameracetat und die Fumarate, die bereits vorgestellt wurden, haben Interferone einen breiteren Wirkmechanismus. Im Folgenden werde ich versuchen, einen guten Überblick zu geben, ohne auf alle Details einzugehen. Und wie immer gilt: Lass dich von MS-Spezialisten beraten, die deine individuelle Situation, deine Wünsche, deine Ängste und deinen allgemeinen Gesundheitszustand kennen. Inhaltsverzeichnis Allgemeine Informationen Wie wird Interferon-beta (Avonex, Betaferon, Extavia, Plegridy, Rebif und Generika) innerhalb der Immuntherapien eingestuft? Wofür ist Interferon-beta zugelassen? Wie sieht die Situation für spezielle Patientengruppen aus? Wer sollte Interferon-beta vermeiden? Wie wirkt Interferon-beta? Wie wird es eingenommen? Wie wirksam ist Interferon-beta (Avonex, Betaferon, Extavia, Plegridy, Rebif und Generika)? Risiken und Nebenwirkungen von Interferon-beta (Avonex, Betaferon, Extavia, Plegridy, Rebif und Generika) Impfungen Quellen Schlussbemerkung Quellen Ich habe die folgenden Quellen für die Erstellung des Inhalts verwendet: Qualitätshandbuch der KKNMS zu Interferon-beta MS-Selfie Infokarten von Prof. Dr. Gavin Giovannoni Deutsches Multiple Sklerose- und Kinderwunsch-Register (DMSKW) Informationen aus dem Interview mit Prof. Dr. Barbara Kornek zur pädiatrischen MS DMSG-Informationen über Interferon-beta DECIMS-Informationen über Interferon-beta Schlussbemerkung Bitte denke daran, dass es nicht das eine gute Medikament gibt, das allen hilft, sondern dass immer abgewogen werden muss, was für die jeweilige Person am besten geeignet ist. Auch andere Krankheiten, persönliche Ziele und Vorlieben müssen berücksichtigt werden. Dein Neurologe und die MS-Schwester sind die richtigen Ansprechpartner und können individuelle Empfehlungen aussprechen. Dieser Artikel dient nur zu Informationszwecken und stellt keine Empfehlung dar. Was dem einen hilft, ist für den anderen vielleicht wirkungslos. Ich hoffe, dass du zusammen mit deinem Neurologen und deiner MS-Schwester schnell die richtige Immuntherapie für dich finden wirst. Und dass du ein erfülltes, glückliches und selbstbestimmtes Leben mit MS führen kannst, unterstützt durch einen gesunden Lebensstil und eine Portion Glück. --- Vielleicht möchtest du auch einen Blick auf die Beiträge zu den anderen Immuntherapien werfen: Dimethylfumarat (Tecfidera) und Diroximelfumarat (Vumerity) Glatirameracetat (Copaxone, Clift) Bis bald und mach das Beste aus Deinem Leben, Nele Mehr Informationen und positive Gedanken erhältst Du in meinem kostenlosen Newsletter. Hier findest Du eine Übersicht zu allen bisherigen Podcastfolgen.

Dr Benjamin Krishna and the Virology & Immunology team at Cambridge University have identified a protein, elevated in the blood of Long Covid patients, that could act as a potential biomarker for the condition.  This week, we spoke to Dr Krishna about their study, published in Science, which sampled the blood of Long Covid patients across several years. They found Interferon Gamma (IFNɣ) at, an average of, six times the normal level.  IFNɣ is a key protein in the body's immune response, a moderator of inflammation and a mediator for fighting infection.  These raised levels of IFNɣ are indicative of the immune system remaining active throughout Long Covid.  The team found that levels returned to normal in patients once they recovered from the disease. These findings could help develop treatment strategies and offer a clear diagnosis for some Long Covid patients.Living with Long Covid? How was your week?Website - https://www.tlcsessions.net/Twitter - @SessionsTlc https://twitter.com/sessionstlcInsta - @tlcsessions https://www.instagram.com/tlcsessions

“If I have seen further, it is because I stand on the shoulders of giants” Sir Isaac Newton famously stated in a letter to polymath scientist, Robert Hooke back in 1675. Today, Dr. Mary Crow, MD, aides Arthritis & Rheumatology launch a series on immunology, for rheumatologists. She is the co-author of the article Standing on Shoulders: Interferon Research, from Viral Interference to Lupus Pathogenesis and Treatment. In this episode, we stand with Dr. Crow to look back at the achievements made by brilliant minds in interferon research and analyze the unbroken line their advancements in rheumatology have led to today's discoveries, with more to com

In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:Patient subgroups to consider for treatment outside guideline criteriaAdverse event and cost-effectiveness considerationsIntegration of patient perspectives in wider treatmentPresenters:Mark S. Sulkowski, MD, FIDSA, FAASLDProfessor of MedicineDirector, Division of Infectious Diseases, Johns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of MedicineDirector of HepatologyStanford University School of MedicinePalo Alto, CaliforniaJacki Chen, PhDPatient Advocate Link to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/4a60GM4Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:Patient subgroups to consider for treatment outside guideline criteriaAdverse event and cost-effectiveness considerationsIntegration of patient perspectives in wider treatmentPresenters:Mark S. Sulkowski, MD, FIDSA, FAASLDProfessor of MedicineDirector, Division of Infectious Diseases, Johns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of MedicineDirector of HepatologyStanford University School of MedicinePalo Alto, CaliforniaJacki Chen, PhDPatient Advocate Link to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/4a60GM4Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:Patient subgroups to consider for treatment outside guideline criteriaAdverse event and cost-effectiveness considerationsIntegration of patient perspectives in wider treatmentPresenters:Mark S. Sulkowski, MD, FIDSA, FAASLDProfessor of MedicineDirector, Division of Infectious Diseases, Johns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of MedicineDirector of HepatologyStanford University School of MedicinePalo Alto, CaliforniaJacki Chen, PhDPatient Advocate Link to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/4a60GM4Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:Patient subgroups to consider for treatment outside guideline criteriaAdverse event and cost-effectiveness considerationsIntegration of patient perspectives in wider treatmentPresenters:Mark S. Sulkowski, MD, FIDSA, FAASLDProfessor of MedicineDirector, Division of Infectious Diseases, Johns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of MedicineDirector of HepatologyStanford University School of MedicinePalo Alto, CaliforniaJacki Chen, PhDPatient Advocate Link to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/4a60GM4Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this week's episode we'll learn more about rare relapse-initiating stem cells in patients with MDS or AML in complete remission post-transplantation, discuss the role of interferon α in erythropoiesis in sickle cell disease, and learn more about how TNFα promotes clonal dominance of KIT D816V+ cells in mastocytosis.

Roger Seheult, MD of MedCram explores elevated interferon levels associated with long covid. See all Dr. Seheult's videos at: https://www.medcram.com/ (This video was recorded on February 23rd, 2024) Roger Seheult, MD is the co-founder and lead professor at https://www.medcram.com He is Board Certified in Internal Medicine, Pulmonary Disease, Critical Care, and Sleep Medicine and an Associate Professor at the University of California, Riverside School of Medicine. MEDCRAM WORKS WITH MEDICAL PROGRAMS AND HOSPITALS: MedCram offers group discounts for students and medical programs, hospitals, and other institutions. Contact us at customers@medcram.com if you are interested. MEDIA CONTACT: Media Contact: customers@medcram.com Media contact info: https://www.medcram.com/pages/media-contact Video Produced by Kyle Allred FOLLOW US ON SOCIAL MEDIA: https://www.facebook.com/MedCram https://twitter.com/MedCramVideos https://www.instagram.com/medcram DISCLAIMER: MedCram medical videos are for medical education and exam preparation, and NOT intended to replace recommendations from your doctor. #covid19 #interferon #coronavirus

TWiN describes a study that reveals activation of endogenous retroviruses in oligodenroglia from patients with traumatic brain injury.  Hosts: Vincent Racaniello, Jason Shepherd, and Timothy Cheung Subscribe (free): Apple Podcasts, Google Podcasts, RSS Links for this episode MicrobeTV Discord Server Activation of endogenous retroviruses in TBI oligodendroglia (Cell Rep) Timestamps by Jolene. Thanks! Music is by Ronald Jenkees Send your neuroscience questions and comments to twin@microbe.tv

In the latest episode of the In Vivo podcast, non-executive chair Peter Bains and Owain Millington, vice president of immunology and head of preclinical, discuss ILC Therapeutics' platform technology, financing plans as well as the pros and cons of running a startup biotech in the UK.

Over 100 years ago, an Austrian psychiatrist cured patients of neurosyphilis by infecting them with malaria. The malaria caused a fever that triggered the patients' immune responses against their neurosyphilis. Patients don't necessarily need to suffer fever, though, to stimulate their immune response. The elevation of their body temperature alone can achieve this effect. Which key antiviral protein is mobilized when body temperature is raised? How can this be safely done to combat infections like COVID-19? On Vital Signs with Brendon Fallon, Dr. Roger Seheult highlights past and present methods used to escalate "virus-blocker" interferon proteins in the body. Dr. Seheult worked as a critical care physician in an intensive care setting during the pandemic. He oversaw the use of hydrotherapy to stimulate patients' interferon response against Coronavirus infection. Interferon is “effective against multiple variants, in fact, all the variants of COVID-19 … It's a very broad tool that our body has … to battle foreign invaders, especially viruses,” says Dr. Seheult. Although lacking modern medical technology, American sanitariums still effectively treated patients during the 1918–1920 flu pandemic. What do their methods tell us about how to counter viral infection today? Dr. Seheult is quadruple board-certified in internal medicine, pulmonary diseases, critical care medicine, and sleep medicine. He is an associate clinical professor of medicine at the University of California. ⭕️ Watch in-depth videos based on Truth & Tradition at Epoch TV

Roger Seheult, MD of MedCram explores the role of interferon in SARS-CoV2 infection, and how hydrotherapy might be an additional tool that can be used in the treatment of infections such as future variants or pandemics where the adaptive immune system cannot be stimulated to act. See all Dr. Seheult's videos at: https://www.medcram.com/ (This video was recorded on November 9th, 2023) Roger Seheult, MD is the co-founder and lead professor at https://www.medcram.com He is Board Certified in Internal Medicine, Pulmonary Disease, Critical Care, and Sleep Medicine and an Associate Professor at the University of California, Riverside School of Medicine. MEDCRAM WORKS WITH MEDICAL PROGRAMS AND HOSPITALS: MedCram offers group discounts for students and medical programs, hospitals, and other institutions. Contact us at customers@medcram.com if you are interested. MEDIA CONTACT: Media Contact: customers@medcram.com Media contact info: https://www.medcram.com/pages/media-contact Video Produced by Kyle Allred FOLLOW US ON SOCIAL MEDIA: https://www.facebook.com/MedCram https://twitter.com/MedCramVideos https://www.instagram.com/medcram DISCLAIMER: MedCram medical videos are for medical education and exam preparation, and NOT intended to replace recommendations from your doctor.

Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]

Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]

Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]

Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]

Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]

Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]

Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]

Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]

TWiV notes the passing of Harald zur Hausen, dengue breaking records in the Americas, inhibition of SARS-CoV-2 infection and inflammation by modulation of type I IFN, and an armed nanobody that protects mice against influenza A and B disease. Hosts: Vincent Racaniello, Kathy Spindler, and Angela Mingarelli Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode MicrobeTV Discord Server MicrobeTV store at Cafepress Position in Rosenfeld Laboratory (pdf) Paul and the Mosquitos (pdf, English) Other childrens books (SMVIROLOGIA) Dengue breaking records in Americas (Nature) Harald zur Hausen, 1936-2023 (Nature) Vincent interviews zur Hausen (ASM) COVID-19 and modulation of IFN (Sci Immunol) Burning down the mouse (TWiV 900) Armed nanobody protects against influenza (Sci Immunol) Click chemistry Nobel prizes (The Nobel Prize) Letters read on TWiV 1033 Timestamps by Jolene. Thanks! Weekly Picks Angela – The Deepest Breath Kathy – Pink snow Vincent – Scientist vs PowerPoint Listener Picks Fernando – The Enigma of Reason by Hugo Mercier and Dan Sperber and Language vs. Reality by Nick Enfield Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

Drs Sapna Patel and Matteo Carlino dive into the data and consider the current and future roles of adjuvant and neoadjuvant therapy. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/989030). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Malignant Melanoma https://emedicine.medscape.com/article/280245-overview Neoadjuvant-adjuvant or Adjuvant-only Pembrolizumab in Advanced Melanoma https://www.nejm.org/doi/10.1056/NEJMoa2211437 Malignant Melanoma Staging https://emedicine.medscape.com/article/2007147-overview Pembrolizumab (Rx) https://reference.medscape.com/drug/keytruda-pembrolizumab-999962 Nivolumab (Rx) https://reference.medscape.com/drug/opdivo-nivolumab-999989 Five-year Analysis of Adjuvant Dabrafenib Plus Trametinib in Stage III Melanoma https://www.nejm.org/doi/10.1056/NEJMoa2005493 Effectiveness of Adjuvant Pembrolizumab vs High-dose Interferon or Ipilimumab for Quality-of-life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/36416836/ TNM Classification of Malignant Tumours, 8th Edition https://www.wiley.com/en-gb/TNM+Classification+of+Malignant+Tumours%2C+8th+Edition-p-9781119263579 RECIST 1.1-Update and Clarification: From the RECIST Committee https://pubmed.ncbi.nlm.nih.gov/27189322/ Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma (NADINA) https://clinicaltrials.gov/ct2/show/NCT04949113 Ipilimumab (Rx) https://reference.medscape.com/drug/yervoy-ipilimumab-999636 An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-risk Melanoma (KEYNOTE-942) https://clinicaltrials.gov/ct2/show/NCT03897881 Adjuvant BRAF-MEK Inhibitors Versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-matched Outcome Analysis https://pubmed.ncbi.nlm.nih.gov/36672358/ Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134 https://pubmed.ncbi.nlm.nih.gov/36166727/

Melanoma and Skin Cancer Awareness Series - 3Being diagnosed with cancer can be a challenging journey, but it doesn't have to define you.  Listen to this fascinating story of one survivor's journey to excellence after a melanoma diagnosis. It will inspire you to keep moving forward and live your best life!Cancer is a diagnosis that can shatter even the strongest among us. Facing an illness like this can make us question our purpose and our ability to withstand the physical and emotional challenges that come with it. My guest Terry Tucker, an inspiring survivor, faced a rare form of melanoma - acral lentiginous melanoma (ALM) diagnosed initially in 2012. Despite being given a low chance of survival, Terry persevered after surgeries and treatments. He believes that going through adversity teaches us something and can make us better human beings. This incredible speaker and man of many talents now finds his purpose in sharing his story and inspiring others to push beyond self imposed  limits. We will dive deeper into how Terry overcame his adversity by facing it with a positive mindset and sheer grit.You can reach Terry at Motivationalcheck.com and on social media Twitter and LinkedIn Listen to Episode 11 to hear my  first conversation with Terry You can find his book “Sustainable Excellence: Ten Principles To Leading Your Uncommon And Extraordinary Life” on AmazonLet's work together to stop skin cancer and save lives! Melanoma and Skin Cancer Awareness SeriesHow do you sail through life? Join me on this endeavor! Support the show. I would love to grow this amazing support community.If you have any thoughts on today's episode, or topics you'd like me to further touch on, reach me through my WEBSITE.Check it out here- SailingThroughLifePodcast.comStay Anchored ⚓Music Credit: Alex_MakeMusic ** Sailing Through Life Podcast is intended to educate, inspire and support you on your personal journey and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. All content is for general informational purposes only. If you are suffering from any psychological or medical conditions, please seek help from a qualified health professional.

Energetic Health Radio with Dr. Henry Ealy – Dr. H is joined by special guest Adam Rowland, a brave man severely injured by the damn shots…a brave man with the courage to take the journey into natural medicine and healing himself. Listen in as he shares what it's really like for the injured, the daily struggles, the emotional challenges, the gaslighting...

Energetic Health Radio with Dr. Henry Ealy – Dr. H is joined by special guest Adam Rowland, a brave man severely injured by the damn shots…a brave man with the courage to take the journey into natural medicine and healing himself. Listen in as he shares what it's really like for the injured, the daily struggles, the emotional challenges, the gaslighting...

PAMPs and DAMPs, complement proteins and MAC, macrophages, Natural Killers and Interferon, MHC molecules...come get acquainted with the players in your innate immune system. For more information, visit http://www.VyvyaneLohMd.com

In Episode 43 of Bladder Cancer Matters, host Rick Bangs talks with bladder cancer survivor, Sue.  Sue's story is both meaningful and inspirational - bladder cancer was her third different cancer diagnosis.  Rick and Sue talk about: The signs and symptoms that Sue experienced with her prior diagnoses for thyroid and breast cancer What drove her to see her doctor when she began experiencing blood in her urine How her bladder cancer treatment experience was different than her prior two bouts with cancer How Sue grappled with whom to tell about her cancer diagnoses and when Her experience with BCG treatments How adding Interferon to her BCG treatments helped her Tips that she has for others who have to undergo cystoscopies How Sue discovered BCAN and how the organization has helped her Sue also volunteers in BCAN's Survivor to Survivor program that matches newly diagnosed bladder cancer patients with survivors who have undergone similar experiences. Never miss an episode of Bladder Cancer Matters by subscribing in your favorite podcasting platform.

Jon joins Immune to discuss the research of his laboratory on understanding how the innate immune system recognizes and responds to pathogens, and his hypothesis that infection infidelities drive innate immunity. Hosts: Vincent Racaniello, Cynthia Leifer, Steph Langel, and Brianne Barker Guest: Jonathan C. Kagan Subscribe (free): Apple Podcasts, Google Podcasts. RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server Approaching the asymptote (Cold Spring Harb Symp Quant Biol) Infection infidelities drive innate immunity (Science) Time stamps by Jolene. Thanks! Music by Steve Neal. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Covid 2/9/22: Interferon λ, published by Zvi on February 9, 2023 on LessWrong. There are two big pieces of pandemic news this week. One is that there is growing alarm about the dangers of avian flu, or H5N1. Likely mammal-to-mammal transmission has been identified, a lot of wild animals are infected, and there is a real danger that this will become a pandemic. I will cover this in its own post. The other is that there are trial results for a new Covid treatment, Interferon λ. It looks super effective. Cuts hospitalizations and deaths in half, with no major side effects. Despite this, there is zero expectation by anyone that it will be available any time soon, and little surprise about this reaction. You see, the trial was done by academics and was in Brazil and Canada. So it doesn't count. Sorry. Executive Summary We have a new drug that cuts Covid risk of hospitalizations and deaths by about half with no major side effects. You can't have it. Maybe ever. Because FDA. FDA Delenda Est. Let's run the numbers. The Numbers Predictions Predictions from Last Week: 210k cases (-8%) and 3,150 deaths (-8%) Results: 238k cases (-6%) and 3,052 deaths (-11%) Predictions for Next Week: 220k cases (-7%) and 2,750 deaths (-10%). Last week I forgot to manually adjust Florida for cases, which I've fixed. That's why the percentages above don't match. Also means my prediction last week for cases was worse than I thought – cases were actually slightly up and I predicted a drop. I expect deaths to continue to drop on schedule. Valentine's Day is not a reporting-relevant holiday, although it is still a date it is important not to forget. Deaths Cases Interferon λ As noted up top: It looks super effective. Cuts hospitalizations and deaths in half, with no major side effects. Despite this, there is zero expectation by anyone that it will be available any time soon, and little surprise about this reaction. Here is their results summary. A total of 933 patients were assigned to receive pegylated interferon lambda (2 were subsequently excluded owing to protocol deviations) and 1018 were assigned to receive placebo. Overall, 83% of the patients had been vaccinated, and during the trial, multiple SARS-CoV-2 variants had emerged. A total of 25 of 931 patients (2.7%) in the interferon group had a primary-outcome event, as compared with 57 of 1018 (5.6%) in the placebo group, a difference of 51% (relative risk, 0.49; 95% Bayesian credible interval, 0.30 to 0.76; posterior probability of superiority to placebo, >99.9%). Results were generally consistent in analyses of secondary outcomes, including time to hospitalization for Covid-19 (hazard ratio, 0.57; 95% Bayesian credible interval, 0.33 to 0.95) and Covid-19–related hospitalization or death (hazard ratio, 0.59; 95% Bayesian credible interval, 0.35 to 0.97). The effects were consistent across dominant variants and independent of vaccination status. Among patients with a high viral load at baseline, those who received pegylated interferon lambda had lower viral loads by day 7 than those who received placebo. The incidence of adverse events was similar in the two groups. I am completely unsurprised both by our government denying people access to life saving medicine as a matter of course. And also completely unsurprised by the complete indifference of the public to our government indefinitely denying everyone access to life-saving medicine. Paxlovid was the last gasp of the old ‘people are dying and we upended our lives to try and stop this, perhaps we should unnecessarily delay less than usual in deploying life saving medicine' principle. This is standard procedure. The FDA exists to deny people life saving medicine. For years. Instead, during that time, they die. No rush. If there isn't enough money to justify paying to get through the process, t...

I have reinvented myself frequently over my professional career. After I graduated from college at The Citadel (where I played NCAA Division I basketball), I was employed in the Marketing Department at the corporate headquarters of Wendy's International in Dublin, Ohio. From there, I worked in hospital administration for Riverside Methodist Hospital in Columbus, Ohio. After getting married and moving to California, I became the Customer Service Manager for an academic publishing company in Santa Barbara. When our daughter was born and we moved to Cincinnati, Ohio, I became a police officer with the Cincinnati Police Department, where I was a SWAT Hostage Negotiator. In 2004, I obtained my Masters degree from Boston University. Following a family relocation to Texas, I started a school security consulting business and coached high school girls basketball. Each time I took on a new job, I had to develop new skills and faced different challenges. There was always a significant learning curve with every new position. But my greatest challenge began in 2012 when I was diagnosed with a rare form of cancer called Acral Lentiginous Melanoma, which presented on the bottom of my foot. By the time the cancer was detected, it had metastasized to a lymph node in my groin. Because my disease is extremely rare I was treated at the world-renowned MD Anderson Cancer Center. I had two surgeries to remove the tumors, and after I healed, I was put on a weekly injection of the drug, Interferon, to help keep the disease from returning. I realize pain and discomfort can beat you to your knees and keep you there if you let it. But I also came to appreciate that I could use my hurting and anguish to harden my mind and make me more resolute. I was no better at dealing with pain and discomfort than the next person. But every day, I found a way to survive, with the knowledge that I would need to do it again the following morning. I wrote my book, Sustainable Excellence, Ten Principles to Leading Your Uncommon and Extraordinary Life to help people find and live their uncommon and extraordinary purpose. The ten principles outlined in the book will provide the bedrock necessary to form the foundation of unshakable beliefs and dedicated behaviors to reinforce your attitude, no matter how much pain you must endure or how many obstacles you must overcome. Sustainable Excellence is available on Amazon (https://www.amazon.com/dp/B08GLGVTVS), Barnes & Noble.com, (https://www.barnesandnoble.com/w/sustainable-excellence-terry-tucker/1137534840), or anywhere you can get a book online. ​ Unfortunately, my cancer experience hasn't ended with me conquering my disease. The melanoma that had plagued me for over five years returned in 2017, and my only treatment option was the amputation of my left foot in 2018. The cancer reemerged again in 2019, requiring multiple operations. In February 2020, an undiagnosed tumor fractured my tibia. My only remedy, in the middle of the COVID pandemic, was an above the knee amputation of my left leg. I also learned I have tumors in both of my lungs. But I refused to be a victim of this malignancy. I vowed to continue my fight. I knew the only way cancer could win is if I gave up or gave in to the disease, or it killed me. In addition to my faith, I use my 4 Truths to guide the decisions I make in my life. These 4 Truths are: 1. Control your mind, or it will control you. 2. Embrace the pain and discomfort we all experience in life and use it to make you a stronger and more determined individual. 3. What you leave behind is what you weave in the hearts of other people. 4. As long as you don't quit - you can never be defeated http://www.motivationalcheck.com

The Landmarks in OncoPharm series returns to discuss adjuvant interferon in melanoma. ECOG 1684: https://pubmed.ncbi.nlm.nih.gov/?term=36649675 Commentary on E1684: https://ascopubs.org/doi/abs/10.1200/JCO.22.02354

JHLT: The Podcast kicks off 2023 with a look back at 2022. Daniel R. Goldstein, MD, Editor-in-Chief of JHLT, joins the JHLT Digital Media Editors for a recap of the past year of The Journal of Heart and Lung Transplantation.   Studies include: Pérez-Carrillo, et al, “Diagnostic value of serum miR-144-3p for the detection of acute cellular rejection in heart transplant patients.” Feb 2022 JHLT Han, et al, “Impact of using higher-risk donor hearts for candidates with pre-transplant mechanical circulatory support.” Feb 2022 JHLT Jackson, et al, “Heart transplant outcomes in cardiac sarcoidosis.” Jan 2022 JHLT Ribeiro, et al, “Ex vivo treatment of cytomegalovirus in human donor lungs using a novel chemokine-based immunotoxin.” Mar 2022 JHLT Moshkelgosha, et al, “Interferon-stimulated and metallothionein expressing macrophages are associated with acute and chronic allograft dysfunction after lung transplantation.” Nov 2022 JHLT   Follow along at www.jhltonline.org/current, or, if you're an ISHLT member, log in at ishlt.org/journal-of-heart-lung-transplantation.  Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

TWiV explains the meaning of vaccine-derived poliovirus found in London sewage, risk of long COVID after infections with Delta or Omicron variants of SARS-CoV-2, and enhancers of innate immune signaling as broad-spectrum antivirals. Hosts: Vincent Racaniello, Dickson Despommier, Alan Dove, Rich Condit, and Kathy Spindler. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Poliovirus in UK sewage (ProMedMail and Science) Poliovirus eradication effort (Science) Long COVID after Delta and Omicron (Lancet) How common is long COVID? (Nature) Immune enhancers as antivirals (Cell Chem Biol) Letters read on TWiV 913 Timestamps by Jolene. Thanks! Weekly Picks Dickson – Count Basie: April in Paris Kathy – Bird aerodynamics & inertia: lay article, video, Nature Rich – NASA Gateway (Thanks Ellis) Alan – Polio Eradication in Nigeria Vincent – The Tyranny of Merit by Michael J. Sandel Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

TWiV reviews recent cases of monkeypox, presence of SARS-CoV-2 RNA but not infectious virus in feces, and the association of autoantibodies to interferons with severe COVID-19. Hosts: Vincent Racaniello, Dickson Despommier, Rich Condit, Kathy Spindler, and Brianne Barker Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Monkeypox in MA (ProMed Mail) Possible monkeypox in NYC (NY Times) Occupational monkeypox, Wisconsin (Emerg Inf Dis) SARS-CoV-2 in feces (Nature) IFN autoantibodies and severe COVID-19 (PNAS) Letters read on TWiV 902 Timestamps by Jolene. Thanks! Weekly Picks Dickson – How to grow food on the moon Brianne – APod May 16: Milky Way over French Alp Hoodoos Kathy – Covid Nationwide data visualization Rich – NIH All of Us Research Program Vincent – Physicians Spreading Misinformation on Social Media — Do Right and Wrong Answers Still Exist in Medicine? Listener Pick Lisa – E.H. Danner Museum of Telephony Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv